Post-Buyout, Genentech's DNA Is Dominant

摘要

When Roche Holding executives held an investor-day briefing in New York in March, Morgan Stanley analyst Andrew Baum had a question that had nothing to do with new drugs, licensing deals, or health-care legislation. "Did the Genen-tech team hide the ties of the Roche executives?" he asked. Richard H. Scheller, a veteran scientist at Genentech, the Silicon Valley biotechnology powerhouse Roche took over last year for $46.8 billion, quipped that he doesn't own one. Turns out his Roche colleagues on the stage, led by Chief Executive Severin Schwan, didn't want him to look out of place so they ditched theirs.